MedTrace Logo

Prospective Observational Study to Investigate the Added Value of the Health Related Quality of Life and Patient Reported Symptoms in the Identification of the Recommended Phase II Dose in Phase I Trials of Molecularly Targeted Therapies.

NCT02857699 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2016-08-05

No results posted yet for this study

Summary

A prospective cohort of 250 patients with solid tumours included in phase I clinical trials of targeted agents will be enrolled. Patients will be treated with MTA in mono therapy or in association with chemotherapy or other targeted agents in 4 large phase I centers.

Patients from trials investigating chemotherapy alone will not be included. Quality of life will be assessed during the treatment period.

Conditions

Sponsors & Collaborators

  • Centre Georges Francois Leclerc

    collaborator OTHER

  • Institut Curie

    lead OTHER

Principal Investigators

  • Xavier PAOLETTI, PhD · Gustave Roussy, Cancer Campus, Grand Paris

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02857699 on ClinicalTrials.gov